Skip to main content

Advertisement

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: a potential oncogenic mechanism and novel therapeutic target

Fig. 1

a) RT-PCRs demonstrating predominant alternative TrkAIII splicing over fully-spliced TrkA expression, compared to GAPDH (GAP), 18S rRNA (18S), MCPyV VP1, small T-antigen (Small T) and large T- antigen (Large T) RT-PCR products, in undiluted (TrkA, TrkAIII, VP1, Small T and Large T), 1:100 diluted (GAP) and 1:1000 diluted (18S) RT reactions of MCC RNAs (500 ng) (MCPyV+) compared to exclusive expression of fully spliced TrkA in RNAs (500 ng) from MCPyV negative (MCPyV) MCC, BCCs, SCCs and normal skin samples, grouped by patient (P) number (10 ul loads per lane). b Box plots demonstrating significantly enhanced TrkAIII percentage of total TrkA (TrkA + TrkAIII) RT-PCR products and significantly reduced TrkA percentage of total (TrkA + TrkAIII) RT-PCR products (upper left and right box plots * p < 0.0001, df = 24), in MCPyV positive (MCPyV+) MCCs compared to MCPyV negative (MCPyV) MCC, BCCs, SCCs and normal skin (NS) samples plus box plots demonstrating a significantly enhanced TrkAIII to 18S rRNA RT-PCR densitometric ratio in MCPyV positive (MCPyV+) MCCs compared to MCPyV negative (MCPyV) MCC, BCCs, SCCs and normal skin (NS) samples (lower left box plot * =0.0009, df = 24) and a significantly reduced TrkA to 18S rRNA RT-PCR densitometric ratio in MCPyV positive (MCPyV+) MCCs compared to MCPyV negative (MCPyV) MCC, BCCs, SCCs and normal skin (NS) samples (lower right box plot * =0.0015, df = 24)

Back to article page